The landscape for mRNA therapeutics is growing, and their potential for moving beyond vaccines and treating both infectious and genetic diseases is great. However, their promise of flexibility, reduced cost, and increased speed to market is offset by the manufacturing challenges around mRNA products encapsulated in lipid nanoparticles (LNPs), the main delivery vehicle of today’s mRNA therapies.
Supported by the UK Vaccine Taskforce, the Centre for Process Innovation (CPI) has established the UK’s first GMP-ready manufacturing site to support a full mRNA-LNP development and manufacturing process. Through process development and scale-up, to manufacture of clinical material, CPI’s integrated approach will help accelerate the development of RNA-based vaccines and therapies with scale-ready manufacturing processes supporting early-stage innovation.
In this webinar, you will learn:
• How we approached construction of a modular RNA-LNP GMP facility employing the Cytiva FlexFactory™ process train in a KUBio™ modular facility
• How a modular mRNA-LNP platform can be applied to meet demands of different RNA products
• New approaches for a more sustainable second-generation mRNA-LNP manufacturing platform
